An assessment by the Statin Intolerance Panel: 2014 update
Abstract
This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
True statin intolerance is uncommon.
“Although musclerelated side effects may occur while on statin therapy, true statin intolerance is uncommon (15,16).”
The citation lists haven’t been fetched yet
References 46 · Cited by 165
- Authors
- Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A.
- Affiliations
- Duke University (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- The University of Texas Southwestern Medical Center (US)
- Emory University (US)
- Corresponding author
- Guyton, John R.
- Venue
- Journal of clinical lipidology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 8
- Issue
- 3
- Pages
- S72-S81
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W1966988082
- Cited by
- 165
- References
- 46
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 18 · 2021: 4 · 2020: 7 · 2019: 16 · 2018: 19 · 2017: 18 · 2016: 27 · 2015: 18 · 2014: 9
- FWCI
- 23.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of clinical lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Amgen
- Genzyme
- Abbott Laboratories
- Merck
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin intolerance, statin adverse effects, statin tolerability, patient decision-making, cardiovascular risk reduction, statin safety
- MeSH terms
- Cardiovascular Diseases, Clinical Trials as Topic, Drug Tolerance, Humans, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review